PROTEIN CORE

蛋白质核心

• 批准号: 8078330
• 负责人: HIROSHI MATSUO
• 金额: $ 23.96万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8078330
• 关键词: Acquired Immunodeficiency Syndrome; American Society of Hematology; Atomic Force Microscopy; Biochemical; Cells; Cessation of life; Core Facility; Core Protein; Deaminase; Deamination; Epitopes; Escherichia coli Proteins; HIV; HIV therapy; HIV-1; Holoenzymes; Human; Human Resources; Individual; Isotope Labeling; Kinetics; Label; Laboratories; Length; Life; Molecular; Peptide Fragments; Peptides; Phase; Procedures; Production; Proteins; Reagent; Research; Research Personnel; Roentgen Rays; Scientist; Services; Solid; System; Testing; Training; United States National Institutes of Health; Variant; Viral Physiology; Virus Diseases; X-Ray Crystallography; abstracting; acrosome stabilizing factor; inhibitor/antagonist; member; mutant; novel; programs; research study; scale up; vif Gene Products

Protein Core Abstract: Dr. Matsuo will direct the Protein Core and a staff of two full-fime scientists. The Protein Core will service the Program Project entitled "Crifical Interactions of APOBECSs: Molecular Approaches to Novel HIV Therapies" by: (i) purifing isotope-labeled and non-labeled proteins from E. coli for use by all program investigators and (ii) purifing proteins from human HEK29S cells for use by all program invesfigators. All proteins will be tested for purity and activity prior to distribution.

蛋白质核心摘要：松尾博士将领导蛋白质核心和两名全职FIME科学家。Protein Core将为题为“APOBECs的关键相互作用：新型HIV疗法的分子方法”的计划项目提供服务：(I)从大肠杆菌中提纯同位素标记和非标记蛋白质，供所有计划研究人员使用；(Ii)从人类HEK29S细胞中提纯蛋白质，供所有计划研究人员使用。所有蛋白质在分发前都将经过纯度和活性测试。